A decade of real‐world clinical experience with 8‐week azithromycin–metronidazole combined therapy in paediatric Crohn's disease
Journal of Pediatric Gastroenterology and Nutrition · 2025-02 · 80 (2) · 300-307
DOI: 10.1002/jpn3.12430 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 09.12.2024. Verfasst von Maria Teresa Fioretti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK. Hauptthemen laut MEDLINE: Crohn Disease, Azithromycin, Metronidazole, Anti-Bacterial Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
The aim of our study was to assess the effectiveness and side‐effect profile of a combination of azithromycin and metronidazole (CD AZCRO) as alternative induction therapy for 8 weeks in mild to moderately active paediatric Crohn's disease (CD).
Methods
We performed a retrospective cohort study (November 2012 to July 2023) of a regional paediatric inflammatory bowel disease service. Disease activity, faecal calprotectin (FC), C‐reactive protein (CRP), erythrocyte sedimentation rate (ESR), haematological parameters and albumin were collected at baseline, 8 and 16 weeks. At Week 8, patients were divided based on (paediatric Crohn's disease activity index) score and inflammatory markers (blood and stool) into: Group 1 clinical remission and Group 2 non‐remission.
Results
A total of 48 patients were initially identified of whom 44 were included in the intention‐to‐treat analysis. After 8 weeks, the overall remission rate was 64%. Of the 38 patients who completed the CD AZCRO course, 28 patients (74%) entered remission (Group 1) and 10 (26%) did not (Group 2). At baseline a shorter disease duration, low weight z score and higher inflammatory burden (ESR, platelets and FC levels) were observed in Group 2. After 8 weeks, Group 1 showed improved CRP levels and higher albumin and haemoglobin levels than Group 2. Median FC declined significantly from 650 mcg/g at baseline to 190 mcg/g at Week 8 in Group 1 ( p < 0.001). At 16 weeks, 23/28 patients (82%) continued in clinical remission. Nausea and vomiting were reported in 4/44 patients.
Conclusions
Our real‐world data demonstrate that CD AZCRO represents an alternative induction therapy for mild to moderate paediatric CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Paediatric Gastroenterology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK.
- Child Life and Health, University of Edinburgh, Royal Hospital for Children and Young People, Edinburgh, UK.
ORCID-Profile: Maria Teresa Fioretti, Richard K Russell
Zitieren
APA
Fioretti, M. T., Gianolio, L., Armstrong, K., Rabone, R. M., Henderson, P., Wilson, D. C., & Russell, R. K. (2025). A decade of real‐world clinical experience with 8‐week azithromycin–metronidazole combined therapy in paediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition, 80(2), 300-307. https://doi.org/10.1002/jpn3.12430
Vancouver
Fioretti MT, Gianolio L, Armstrong K, Rabone RM, Henderson P, Wilson DC, et al. A decade of real‐world clinical experience with 8‐week azithromycin–metronidazole combined therapy in paediatric Crohn's disease. Journal of Pediatric Gastroenterology and Nutrition. 2025;80(2):300-307. doi:10.1002/jpn3.12430
BibTeX
@article{Fioretti2025,
author = {Fioretti, Maria Teresa and Gianolio, Laura and Armstrong, Katherine and Rabone, Rosalind M and Henderson, Paul and Wilson, David C and Russell, Richard K},
title = {A decade of real‐world clinical experience with 8‐week azithromycin–metronidazole combined therapy in paediatric Crohn's disease},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2025},
volume = {80},
number = {2},
pages = {300--307},
doi = {10.1002/jpn3.12430}
}
EUVIMED